Philippines may re-introduce controversial dengue vaccine
The Philippines is considering re-introducing a dengue vaccine whose use was ceased because of links to several deaths.
List view / Grid view
The Philippines is considering re-introducing a dengue vaccine whose use was ceased because of links to several deaths.
Rising temperatures will likely accelerate the spread of vector-borne diseases, resulting in an increased demand for vaccines. European Pharmaceutical Review investigates a Morgan Stanley report on the pharmaceutical beneficiaries of climate change.
A vaccine containing the DNA of HIV is poised to enter a Phase II trial, making it the first vaccine of its kind to do so.
The health minister for the Democratic Republic of the Congo has stated an experimental Ebola vaccine will not be trialled in the country.
The successful pilot programme could represent an important step forward in biopharmaceutical supply chain innovation.
A medical centre in Hong Kong had 76 boxes of an HPV vaccine seized after a complaint from a patient who experienced adverse side effects.
Comparison of the Sartorius Claristep Filtration System with standard sample preparation using syringe filters.
A recent report has presented an argument for updating vaccine development during health emergencies to increase efficiency.
Pharmaceutical company, Sanofi, will eliminate jobs in France and Germany and end new in-house cardiology research programmes.
Decreased supply of anti-rabies vaccines (ARVs) in Delhi causes outbreak of the disease.
Novel influenza A vaccine has been administered to first patients in Phase IIb trial.
Scientists have developed a single vaccination approach to simultaneously combat influenza and pneumococcal infections.
Vaccinations have begun in a phase I human clinical trial testing a freeze-dried, temperature-stable formulation of an experimental tuberculosis vaccine candidate. Nikki Withers speaks to Dr Daniel Hoft and Christopher Fox about the formulation process and what this means for vaccine development going forward.
A new vaccine for colorectal cancer has proven to be safe in a small sample of human subjects, opening the way for the next phase of testing.
A $100 million investment has been made to support long-term vaccine manufacturing capabilities in the US.